Upcoming Events in the World CNS Series
Providing Industry-Dedicated Content & Uniting CNS Drug Developers
Following a year of significant pharma acquisitions, approvals of transformative drugs the first of their kind, and a surge of financial backing to bolster innovation in new targets and preclinical pipelines, 2025 is set to continue this momentum, with more companies prioritizing neuroscience drug development than ever before, thanks to:
Huge breakthroughs in neuroscience discovery with state-of-the-art screening technologies
In vitro preclinical model advances, including 3D brain organoids and IPSC-derived microglia
Implementation of novel blood-based and digital biomarkers for non-invasive and objective measurements
Next-generation rodent, pig, and NHP models with enhanced human relevance and translatability
Brand new drug delivery innovations to overcome the blood-brain barrier and unlock deeper brain regions
Clinical innovations to navigate heterogeneous patient populations, streamline recruitment, and navigate regulatory challenges
Translate Novel Targets Beyond Aβ, Decipher Disease Complexity, Enhance α-Synuclein Detection & Advance the Reality of Blood-Based Biomarkers to Innovate More Transformative & Commercially Viable Disease-Modifying Neurodegenerative Therapies
Rethinking Transformative ALS Targets, Seek Translational Biomarkers & Propel More Clinical Approvals
Discovering, Validating & Implementing Novel Translatable Neuroinflammatory & Neurodegenerative Biomarkers
Advancing Translatable Systemic & Local Delivery Systems to Maximize CNS Uptake & Safely Administer to Specific Brain Regions
Download the Prospectus:
Get a comprehensive overview of the upcoming events within the World CNS Series portfolio. If you have any questions, get in touch at info@hansonwade.com
